Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study

Abstract

Previous studies have reported that protease inhibitors (PIs) can contribute to glycaemic alterations. However, there are few trials examining the direct effect of a single PI. The objective of the study was to evaluate the modifications of glucose and lipid profiles after a switch from lopinavir/ritonavir (LPV/r) to atazanavir, used as ritonavir-boosted (ATV/r) or un-boosted. We conducted a retrospective observational cohort study on the effect of ATV/(r) on glycaemic metabolism (ATAGLU) in patients with undetectable levels of HIV-RNA who switched from LPV/r. In total, 235 patients treated for 48 weeks with LPV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) and with undetectable HIV-RNA were included: 134 continued LPV/r after the initial 48 weeks and 101 switched to ATV(/r) (18.3% to ATV; 24.7% to ATV/r). A significant decrease in mean glucose level and insulin resistance was observed in patients who switched to ATV(/r). The mean cholesterol triglyceride levels increased in the LPV/r group and decreased among the patients who switched. A significant increase of CD4 T cells with undetectable levels of HIV-RNA was observed in all groups. The long-term results obtained in this real-life study suggest that patients who have achieved initial suppression on a regimen including LPV/r + two NRTIs can switch to ATV/(r) + two NRTIs with an improvement in lipid and glycaemic metabolism.

Keywords

HIV AIDS treatment protease inhibitor cardiovascular risk switch study atazanavir lopinavir ritonavir antiretroviral therapy glucose glycaemic metabolism insulin resistance

Get full access to this article

View all access options for this article.

References

Dubè

. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1647–1675.

Tebas

. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention and treatment options. J Acquir Immun Def Syndr 2008; 49: S86–S92.

Brown

Tassiopoulos

Bosch

. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33: 2244–2249.

Samaras

. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50: 499–505.

Brown

Cole

. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179–1184.

Justman

Benning

Danoff

. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298–302.

Squires

Lazzarin

Gatell

. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Def Syndr 2004; 36: 1011–1019.

Noor

Parker

O’Mara

. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18: 2137–2144.

Bonora

Kiechl

Willeit

. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 1998; 47: 1643–1649.

10.

Ascaso

Pardo

Real

. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320–3325.

11.

Nix

Tien

. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep 2014; 11: 271–278.

12.

Lake

Currier

. Metabolic disease in HIV infection. Lancet Infect Dis 2013; 13: 964–975.

13.

Kalra

Agrawal

. Diabetes and HIV: current understanding and future perspectives. Curr Diab Rep 2013; 13: 419–427.

14.

Squires

Young

DeJesus

. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted Atazanavir/Lamivudine. HIV Clin Trials 2012; 13: 233–244.

15.

Guffanti

Caumo

Galli

. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. Eur J Endocrinol 2007; 156: 503–509.

16.

Erlandson

Kitch

Tierney

. Impact of randomized antiretroviral therapy initiation on glucose metabolism: AIDS clinical trials group study A5224s. AIDS 2014; 28: 1451–1461.

17.

Martinez

Gonzalez-Cordon

Ferrer

. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Med 2014; 15: 330–338.

18.

McComsey

Kitch

Daar

. Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791–1801.

19.

Ortiz

Dejesus

Khanlou

. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS 2008; 46: 1389–1397.

20.

Soriano

García-Gasco

Vispo

. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008; 61: 200–205.

21.

Mallolas

Podzamczer

Milinkovic

. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009; 51: 29–36.

22.

Agarwala S, Eley T, Child M, et al. Pharmacokinetic effects of coadministration of atazanavir and tenofovir at steady state. In: Abstracts of the third IAS conference on HIV pathogenesis and treatment, Rio de Janeiro, 2005. Poster WePe3.3C07. Geneva, Switzerland: International AIDS Society.

23.

Calcagno

Bonora

Tettoni

. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. J Acquir Immune Defic Syndr 2009; 52: 431–432.

24.

Pavie

Porcher

Torti

. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother 2011; 66: 2372–2378.

25.

Ghosn

Carosi

Moreno

. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010; 15: 993–1002.

26.

Castagna

Galli

Gianotti

. Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens. New Microbiol 2013; 36: 239–249.

27.

Carr

Samaras

Burton

. A syndrome of peripheral lipodistrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51–F58.